IE
PTCT icon

Israel Englander’s PTC Therapeutics PTCT Stock Holding History

Israel Englander’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-75,000
Closed -$3.61M – 3677
2015
Q2 		$3.61M Buy
+75,000
New +$4.38M 0.01% 1582

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Israel Englander's PTCT Position: Q2 2026 in Review

Israel Englander opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 46,494 shares worth $3.79M. The stake represents ﹤0.01% of the portfolio and ranks #3259 among its holdings. This is a return to the name: Israel Englander previously reported a position in PTCT as recently as Q4 2025.

Israel Englander first reported a position in PTCT in Q2 2014 and has held it in 40 quarters since. The position peaked at $64.8M in Q3 2025. 381 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Israel Englander held 46,494 shares of PTC Therapeutics worth $3.79M as of Q2 2026.
  • PTC Therapeutics was a new Israel Englander position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3259 holding.
  • Israel Englander first reported a position in PTC Therapeutics in Q2 2014 and has held it in 40 quarters since.
  • Israel Englander's PTC Therapeutics position peaked at $64.8M in Q3 2025.
  • 381 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.